New Hampshire Senate Approves Medical Cannabis Home Cultivation Bill

Concord, N.H. - February 6, 2020 (Investorideas.com Newswire) On Thursday, the New Hampshire Senate passed a bill in a voice vote that would allow patients and caregivers to grow a limited supply of cannabis. SB 420 will now proceed to the House of Representatives, which has passed similar legislation in the past with strong majority support.

SB 420 would allow possession of three mature plants, three immature plants, and 12 seedlings for each patient. Under current law, home cultivation is classified as a felony. There are now more than 8,000 Granite Staters that are enrolled in the state's therapeutic cannabis program. This bill is critically important because many patients are unable to afford dispensary products, which are not covered by health insurance. For some patients, home cultivation is simply the best, most affordable option.

Last year, the New Hampshire House and Senate passed a similar bill that would have allowed patients and caregivers to grow a limited supply of cannabis. Sadly, Gov. Chris Sununu vetoed the bill. The House voted to override his veto, but the Senate fell three votes short of doing so.

Statement from Matt Simon, New England political director at the Marijuana Policy Project:

"This bill presents Gov. Sununu with a great opportunity to continue his evolution on cannabis policy. Patients all over New Hampshire are benefitting from cannabis as an alternative to opioids, but many are unable to afford the expensive products that are available at dispensaries. Home cultivation is a cost-effective option that is available to patients and adults in all neighboring jurisdictions, and there is no good reason it should remain a crime for patients in the 'Live Free or Die' state."

The Marijuana Policy Project is the nation's largest marijuana policy organization. It has been a leading advocate for federal marijuana policy reforms since its founding in 1995, and it has played a leading role in most major state-level reforms that have occurred over the past two decades. For more information, visit https://www.mpp.org.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Buy a cannabis guest post on Investorideas.com